|
1）Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med. 1995; 1: 1148-54
|
|
|
|
2）Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet. 1994; 6: 335-41
|
|
|
|
|
|
3）Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003; 80: 148-58
|
|
|
|
|
|
4）Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011; 12: 341-55
|
|
|
|
|
|
5）Ylä-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther. 2012; 20: 1831-2
|
|
|
|
|
|
6）Kuroda M, Bujo H, Aso M, et al. Adipocytes as a vehicle for ex vivo gene therapy: Novel replacement therapy for diabetes and other metabolic diseases. J Diabetes Invest. 2011; 2, 333-40
|
|
|
|
|
|
7）Rip J, Nierman MC, Ross CJ, et al. Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol. 2006; 26: 1236-45
|
|
|
|
|
|
8）Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol. 2008; 28: 2303-4
|
|
|
|
|
|
9）Gaudet D, de Wal J, Tremblay K, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl. 2010; 11: 55-60
|
|
|
|
|
|
10）Gaudet D, Méthot J, Déry S, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013; 20: 361-9
|
|
|
|
|
|
11）Carpentier AC, Frisch F, Labbé SM, et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab. 2012; 97: 1635-44
|
|
|
|
|
|
12）Wierzbicki AS, Viljoen A. Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency. Expert Opin Biol Ther. 2013; 13: 7-10
|
|
|
|
|
|
13）Chen Z, Chu D, Castro-Perez JM, et al. AAV8-mediated long-term expression of human LCAT significantly improves lipid profiles in hCETP; Ldlr(+/-) mice. J Cardiovasc Transl Res. 2011; 4: 801-10
|
|
|
|
|
|
14）Shibasaki M, Takahashi K, Itou T, et al. Alterations of insulin sensitivity by the implantation of 3T3-L1 cells in nude mice. A role for TNF-alpha? Diabetologia. 2002; 45: 518-26
|
|
|
|
|
|
15）Shibasaki M, Takahashi K, Itou T, et al. A PPAR agonist improves TNF-alpha-induced insulin resistance of adipose tissue in mice. Biochem Biophys Res Commun. 2003; 309: 419-24
|
|
|
|
|
|
16）Ito M, Bujo H, Takahashi K, et al. Implantation of primary cultured adipocytes that secrete insulin modifies blood glucose levels in diabetic mice. Diabetologia. 2005; 48: 1614-20
|
|
|
|
|
|
17）Fraser JK, Wulur I, Alfonso Z, et al. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol. 2006; 24: 150-4
|
|
|
|
|
|
18）Sugihara H, Yonemitsu N, Miyabara S, et al. Primary cultures of unilocular fat cells: characteristics of growth in vitro and changes in differentiation properties. Differentiation. 1986; 31: 42-9
|
|
|
|
|
|
19）Kuroda M, Aoyagi Y, Asada S, et al. Ceiling culture-derived proliferative adipocytes are a possible delivery vehicle in enzyme replacement therapy in lecithin:cholesterol acyltransferase deficiency. Open Gene Ther. J. 2011; 4, 1-10
|
|
|
|
|
|
20）Santamarina-Fojo S, Hoeg JM, Assman G, et al. Lecithin cholesterol acyltransferase deficiency and fish eye disease. In: Scriver CR, et al. editors. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill Inc; 2001. p.2817-33
|
|
|
|
|
|
21）Asada S, Kuroda M, Aoyagi Y, et al. Disturbed apolipoprotein A-I-containing lipoproteins in fish-eye disease are improved by the lecithin:cholesterol acyltransferase produced by gene-transduced adipocytes in vitro. Mol. Genet. Metab. 2011; 102: 229-31
|
|
|
|
|
|
22）Kuroda M, Holleboom AG, Stroes E, et al. Lipoprotein subfractions highly associated with renal damage in familial LCAT deficiency. Arterioscler Thromb Vasc Biol. 2014; 34: 1756-62
|
|
|
|
|
|
23）Asada S, Kuroda M, Aoyagi Y, et al. Ceiling culture-derived proliferative adipocytes retain high adipogenic potential suitable for use as a vehicle for gene transduction therapy. Am J Physiol Cell Physiol. 2011; 301: C181-5
|
|
|
|
|
|
24）Aoyagi Y, Kuroda M, Asada S, et al. Fibrin glue is a candidate scaffold for long-term therapeutic protein expression in spontaneously differentiated adipocytes in vitro. Exp Cell Res. 2012; 318: 8-15
|
|
|
|
|
|
25）Aoyagi Y, Kuroda M, Asada S, et al. Fibrin glue increases the cell survival and the transduced gene product secretion of the ceiling culture-derived adipocytes transplanted in mice. Exp Mol Med. 2011; 43: 161-7
|
|
|
|
|